NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says

MT Newswires Live06-30

NewAmsterdam Pharma's (NAMS) obicetrapib could be a strong second option for patients with high LDL cholesterol, particularly if an ongoing phase 3 trial can recapitulate a 20% reduction in major adverse cardiovascular events, RBC Capital Markets said in a note Tuesday.

The brokerage said its survey showed 23% of 174 patients are not satisfied with existing treatment regimens, while a "significant" niche of patients may use obicetrapib as an add-on or switch therapy, suggesting an addressable market of up to $40 billion. RBC said it now estimates US sales of about $2.1 billion by 2035.

Additional benefits offered by obicetrapib are potential differentiators that may appeal to key opinion leaders, but the brokerage said its survey showed that these will not be a major driver of use.

RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47, with an outperform, speculative risk rating.

Price: 33.86, Change: -0.01, Percent Change: -0.03

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647568952?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 23:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647568952","market":"hk","top_or_hot":-1,"title":"NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says","media":"MT Newswires Live","content":"<html><body><p> NewAmsterdam Pharma's (NAMS) obicetrapib could be a strong second option for patients with high LDL cholesterol, particularly if an ongoing phase 3 trial can recapitulate a 20% reduction in major adverse cardiovascular events, RBC Capital Markets said in a note Tuesday.</p><p>The brokerage said its survey showed 23% of 174 patients are not satisfied with existing treatment regimens, while a \"significant\" niche of patients may use obicetrapib as an add-on or switch therapy, suggesting an addressable market of up to $40 billion. RBC said it now estimates US sales of about $2.1 billion by 2035.</p><p>Additional benefits offered by obicetrapib are potential differentiators that may appeal to key opinion leaders, but the brokerage said its survey showed that these will not be a major driver of use.</p><p>RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47, with an outperform, speculative risk rating.</p><p>Price: 33.86, Change: -0.01, Percent Change: -0.03</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-30 23:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> NewAmsterdam Pharma's (NAMS) obicetrapib could be a strong second option for patients with high LDL cholesterol, particularly if an ongoing phase 3 trial can recapitulate a 20% reduction in major adverse cardiovascular events, RBC Capital Markets said in a note Tuesday.</p><p>The brokerage said its survey showed 23% of 174 patients are not satisfied with existing treatment regimens, while a \"significant\" niche of patients may use obicetrapib as an add-on or switch therapy, suggesting an addressable market of up to $40 billion. RBC said it now estimates US sales of about $2.1 billion by 2035.</p><p>Additional benefits offered by obicetrapib are potential differentiators that may appeal to key opinion leaders, but the brokerage said its survey showed that these will not be a major driver of use.</p><p>RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47, with an outperform, speculative risk rating.</p><p>Price: 33.86, Change: -0.01, Percent Change: -0.03</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2647568952","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647568952","pubTimestamp":1782835061,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"NewAmsterdam Pharma's  obicetrapib could be a strong second option for patients with high LDL cholesterol, particularly if an ongoing phase 3 trial can recapitulate a 20% reduction in major adverse cardiovascular events, RBC Capital Markets said in a note Tuesday.The brokerage said its survey showed 23% of 174 patients are not satisfied with existing treatment regimens, while a \"significant\" niche of patients may use obicetrapib as an add-on or switch therapy, suggesting an addressable market of up to $40 billion. RBC said it now estimates US sales of about $2.1 billion by 2035.Additional benefits offered by obicetrapib are potential differentiators that may appeal to key opinion leaders, but the brokerage said its survey showed that these will not be a major driver of use.RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47, with an outperform, speculative risk rating.Price: 33.86, Change: -0.01, Percent Change: -0.03","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","NAMS":"NEWAMSTERDAM PHARMA CO NV","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4207":"综合性银行","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A"},"translate_title":"加拿大皇家银行资本市场表示，新阿姆斯特丹制药公司的Obicetrapib可能会占领市场份额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NAMS":1},"content_text":"NewAmsterdam Pharma's (NAMS) obicetrapib could be a strong second option for patients with high LDL cholesterol, particularly if an ongoing phase 3 trial can recapitulate a 20% reduction in major adverse cardiovascular events, RBC Capital Markets said in a note Tuesday.The brokerage said its survey showed 23% of 174 patients are not satisfied with existing treatment regimens, while a \"significant\" niche of patients may use obicetrapib as an add-on or switch therapy, suggesting an addressable market of up to $40 billion. RBC said it now estimates US sales of about $2.1 billion by 2035.Additional benefits offered by obicetrapib are potential differentiators that may appeal to key opinion leaders, but the brokerage said its survey showed that these will not be a major driver of use.RBC Capital Markets raised its price target on NewAmsterdam Pharma to $51 from $47, with an outperform, speculative risk rating.Price: 33.86, Change: -0.01, Percent Change: -0.03","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647568952","isCrawlerRequest":true}